Anupam Rasayan revenue jumps 65% in FY26 as margins slip to 23%
Revenue growth outpaced profitability in FY26, with Q4 profit dropping 11% year-on-year.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- FY26 revenue grew 65% year-on-year.
- EBITDA margins compressed to 23% from 28% in the prior year.
- Q4 net profit fell 11% compared to the same quarter last year.
Why this matters
The sharp divergence between top-line expansion and margin contraction suggests the company is trading profitability for scale. While the Jayhawk acquisition and new contracts provide a growth narrative, the margin decline is a clear headwind for shareholders.
What we're watching
- Whether the company can stabilize margins in FY27.
- The integration progress of the Jayhawk acquisition.
- Revenue contribution from the Bliss GVS Pharma deal.
The full read
Anupam Rasayan posted 65% revenue growth for FY26, but the headline figure masks a thinning bottom line. EBITDA margins retreated to 23% from 28% in the prior year. The pressure on profitability extended into the final quarter, where net profit fell 11% year-on-year.
Growth is becoming expensive.
The company continues to lean on the Jayhawk acquisition and the Bliss GVS Pharma contract to drive its expansion, yet the margin compression indicates that scaling these new assets without further diluting its core profitability remains the primary challenge for the management team in the coming fiscal year.
Questions answered
- How did Anupam Rasayan perform in FY26?
- The company recorded a 65% increase in revenue year-on-year. However, EBITDA margins fell to 23% from 28%.
- What was the trend in Q4 profitability?
- Q4 profit dropped 11% compared to the same period in the previous year.
- Are there new strategic developments mentioned?
- The release references the Jayhawk acquisition and the Bliss GVS Pharma deal, though these were previously disclosed.
Story so far
All notes on ANURAS →- Today · 8:27 PM IST Anupam Rasayan revenue jumps 65% in FY26 as margins slip to 23%
- 1d ago Anupam Rasayan buys Bliss GVS Pharma for ₹2,200 cr
- 1d ago Anupam Rasayan buys 74.20% of Bliss GVS Pharma